Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Game Changer - Claritas Brief Part 4

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 25, 2022 8:25pm

168 Views

Post# 34360607

RE:Game Changer - Claritas Brief Part 4

What is a "paid Claritas pumpert" is it someone who has access to confidential information....and from making use of such
information in trading in the company’s securities before the information has been fully disclosed to the public... in a reasonable period of
time for dissemination of the information has passed....pumpert?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market